Hanmi Pharm launches complex treatment of rosuvastatin and ezetimibe
Hanmi Pharm(CEO Kwan-soon Lee) launched ‘Rosuzet,’ a complex drug combining ‘rosuvastatin,’ a substance of hyperlipidemia treatment, and ‘ezetimibe’ for the first time in the world, the company announced on the 12th. The combination of the two substances both inhibits cholesterol synthesis and hi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
